Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: buyhiman who wrote (15153)	2/16/1998 5:09:00 PM
From: Henry Niman	Respond to of 32384

Carl, My understanding is that Phase II breast cancer trials are a top priority. Bernie mentioned that in his H&Q summary. I expect the trials to begin soon (next few months). I'm not sure what is being presented at the upcoming conferences. One is April 8 (and I'm not sure which conference it is) and another is ASCO in May. There are two ongoing Phase I trials that use Panretin in combination with Tamoxifen. I think that the initial chemoprentive data in the PNU rat model gave rise to these two government studies. It is conceivable (but I haven't verified), that initial data (on Tamoxifen combined with Panretin) could be presented at one of these upcoming conferences.